Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nuvectis Pharma, Inc.

8.11
-0.5300-6.13%
Post-market: 8.740.6300+7.77%18:24 EDT
Volume:87.95K
Turnover:725.74K
Market Cap:191.68M
PE:-7.22
High:8.86
Open:8.52
Low:8.11
Close:8.64
Loading ...

Nuvectis Pharma Inc. Conducted Annual Stockholders Meeting

Reuters
·
14 Jun

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

Reuters
·
17 May

10% Owner Marlio Charles Mosseri Reports Acquisition of Nuvectis Pharma Inc. Common Shares

Reuters
·
14 May

10% Owner Marlio Charles Mosseri Acquires Common Shares of Nuvectis Pharma Inc

Reuters
·
10 May

Maxim Group Keeps Their Buy Rating on Nuvectis Pharma (NVCT)

TIPRANKS
·
07 May

Nuvectis Pharma Q1 EPS $(0.27) Misses $(0.25) Estimate

Benzinga
·
06 May

BRIEF-Nuvectis Pharma Q1 Net Income USD -5.332 Million

Reuters
·
06 May

Nuvectis Pharma Q1 EPS USD -0.27

THOMSON REUTERS
·
06 May

Nuvectis Pharma Inc: Extending Projected Cash Runway Into 1Q2027

THOMSON REUTERS
·
06 May

Press Release: Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

Dow Jones
·
06 May

Buy Rating for Nuvectis Pharma: Promising Phase 1 Trial Results of NXP900 Highlight Potential in Combination Therapies

TIPRANKS
·
02 May

Nuvectis Pharma Price Target Raised to $15.00/Share From $11.00 by HC Wainwright & Co.

Dow Jones
·
30 Apr

Promising Developments in Nuvectis Pharma’s NXP900 Drive Buy Rating

TIPRANKS
·
30 Apr

Nuvectis Pharma, Inc. : H.c. Wainwright Raises Target Price to $15 From $11

THOMSON REUTERS
·
30 Apr

Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025

Insider Monkey
·
30 Apr

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

GlobeNewswire
·
30 Apr

Nuvectis Pharma Initiated at Buy by Maxim Group

Dow Jones
·
03 Apr

Maxim Initiates Nuvectis Pharma at Buy With $17 Price Target

MT Newswires Live
·
02 Apr

Nuvectis Pharma Inc : Maxim Group Initiates Coverage With Buy Rating; Price Target $17

THOMSON REUTERS
·
02 Apr

Nuvectis Pharma Announces Upcoming Presentations for Nxp900 at the 2025 American Association for Cancer Research Meeting

THOMSON REUTERS
·
26 Mar